Effectiveness and safety of carteolol 0.5% eye drops in the treatment of mild ocular hypertension

To assess the ocular hypotensive effect of carteolol 0.5%, a randomized, do uble-masked placebo-controlled (vehicle), multicenter study of 2 parallel g roups was initiated Forty patients with early primary open-angle glaucoma o r simple mild ocular hypertension were enrolled. The test treatment lasted 2 weeks, with twice daily instillations. The mean decrease in intraocular p ressure on day 15 was significantly greater in the carteolol 0.5% group: 23 % and 18% (2 and 12 hours post-dose, respectively).